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Abstract
Background: The protective role of high-density lipoprotein (HDL) in the cardiovascular system
is related to its role in the reverse transport of cholesterol from the arterial wall to the liver for
subsequent excretion via the bile. Scavenger receptor class B type I (SR-BI) binds HDL and
mediates selective uptake of cholesterol ester and cellular efflux of cholesterol to HDL. The role
of SR-BI in atherosclerosis has been well established in murine models but it remains unclear
whether SR-BI plays an equally important role in atherosclerosis in humans. The aim of this study
was to investigate the expression of SR-BI and its isoforms in human macrophages and
atherosclerotic plaques.
Methods: The effect of hypoxia and minimally modified low-density lipoprotein (mmLDL), two
proatherogenic stimuli, on SR-BI expression was studied in human monocyte-derived macrophages
from healthy subjects using real-time PCR. In addition, SR-BI expression was determined in
macrophages obtained from subjects with atherosclerosis (n = 15) and healthy controls (n = 15).
Expression of SR-BI isoforms was characterized in human atherosclerotic plaques and macrophages
using RT-PCR and DNA sequencing.
Results: SR-BI expression was decreased in macrophages after hypoxia (p < 0.005). In contrast,
SR-BI expression was increased by exposure to mmLDL (p < 0.05). There was no difference in SR-
BI expression in macrophages from patients with atherosclerosis compared to controls. In both
groups, SR-BI expression was increased by exposure to mmLDL (p < 0.05). Transcripts
corresponding to SR-BI and SR-BII were detected in macrophages. In addition, a third isoform,
referred to as SR-BIII, was discovered. All three isoforms were also expressed in human
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atherosclerotic plaque. Compared to the other isoforms, the novel SR-BIII isoform was predicted
to have a unique intracellular C-terminal domain containing 53 amino acids.
Conclusion: We conclude that SR-BI is regulated by proatherogenic stimuli in humans. However,
we found no differences between subjects with atherosclerosis and healthy controls. This indicates
that altered SR-BI expression is not a common cause of atherosclerosis. In addition, we identified
SR-BIII as a novel isoform expressed in human macrophages and in human atherosclerotic plaques.
Background
The presence of lipid-loaded macrophages (foam cells) in
the vascular wall is one of the hallmarks of atherosclero-
sis. High levels of low-density lipoprotein (LDL) choles-
terol increase the risk of atherosclerosis and the lipids
accumulated in the macrophages are derived mainly from
modified forms of LDL. Oxidation of LDL is believed to be
the major modification of LDL cholesterol in vivo [1]. As
the atherosclerotic plaque increases in size due to accumu-
lation of lipid and fibrous elements, local supply of oxy-
gen and nutrients may become insufficient. In advanced
atherosclerotic plaques, zones of hypoxia have been iden-
tified [2,3].
The level of high-density lipoprotein (HDL) cholesterol is
inversely related to the risk of developing atherosclerosis.
A proposed mechanism for the athero-protective role of
HDL is the transfer of cholesterol from the arterial wall via
the liver to the bile, a process known as reverse cholesterol
transport [4]. Scavenger receptor class B type I (SR-BI; also
known as CLA-1) has been shown to mediate selective
uptake of cholesterol esters from HDL particles into cells
[5]. Moreover, SR-BI mediates cholesterol efflux in vitro
[6,7] and has been suggested to contribute to cellular cho-
lesterol efflux also in vivo. Therefore, SR-BI may be of
importance also for the first step in reverse cholesterol
transport, i.e. the removal of cholesterol from the arterial
wall [4].
The role of SR-BI in HDL metabolism and atherosclerosis
has been well established in murine models. Experiments
in rodents have shown that SR-BI is expressed in tissues
with selective cholesterol uptake, e.g. liver, adrenals, ova-
ries and testes [5,8]. Hepatic overexpression of SR-BI in
transgenic mice decreases the development of atheroscle-
rosis in cholesterol-fed LDL receptor knockout (KO) mice
[9]. Recent studies have demonstrated that lack of SR-BI
expression in macrophages increases atherosclerotic
lesion formation in mice [10]. The link between human
SR-BI and atherosclerosis in man is less well established.
Human SR-BI mediates selective cholesterol uptake into
cells and displays a tissue distribution similar to that in
rodents [11,12]. SR-BI expression has been detected in
human atherosclerotic plaques [13] and variants of the
human SR-BI gene have been associated to lipid abnor-
malities [14,15]. Recently, a variant of the human SR-BI
promoter, that displays decreased expression, has been
associated to increased plasma HDL cholesterol levels
[16]. Therefore, decreased macrophage expression of
human SR-BI may be a mechanism that promotes the
development of atherosclerosis.
The aim of this study was to investigate the expression of
SR-BI in human macrophages and atherosclerotic
plaques.
Methods
Subjects and samples
Patients diagnosed with myocardial infarction or unstable
angina pectoris were identified via the INTERGENE study,
which is a population study recruiting subjects from
Västra Götaland, Sweden. For details on the sampling and
procedures in the INTERGENE study, see Berg et al [17].
First-degree relative (siblings, children or parents) of the
patients were screened by ultra-sound examination
(Sequoia ultra sound scanner) of the intima thickness of
the carotid and femoral arteries to determine the extent of
atherosclerosis. Fifteen subjects with sub-clinical athero-
sclerosis were recruited to this study (the macrophage
INTERGENE study). The inclusion criteria for the athero-
sclerotic group were at least one atherosclerotic plaque in
the carotid or femoral arteries and a verified family history
of myocardial infarction or unstable angina pectoris, as
documented in the INTERGENE study. Fifteen healthy
control subjects matched by sex and age, which had no
such family history, were also recruited from the INTER-
GENE population study. The exclusion criteria for both
groups were, age <40 years, diabetes mellitus, clinical car-
diovascular disease, smoking during the last 10 years,
severe hypercholesterolemia, current infection (C-reactive
protein >5 mg/L), and severe chronic disease. Additional
exclusion criteria for the control group were hypertension.
Specimens from atherosclerotic carotid arteries were
obtained from two females and two males undergoing
carotid endarterectomy (n = 4).
The lipid analyses were performed at the Wallenberg Lab-
oratory and the remaining biochemical analyses at the
central laboratory at Sahlgrenska University Hospital.
Triglyceride and cholesterol levels were analysed by fully
enzymatic techniques [18,19]. LDL cholesterol wasBMC Cardiovascular Disorders 2005, 5:25 http://www.biomedcentral.com/1471-2261/5/25
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calculated as described by Friedewald et al. [20]. HDL was
determined after precipitation of apolipoprotein (apo) B-
containing lipoproteins with manganese chloride and
dextran sulfate. The clinical and biochemical characteris-
tics of the study groups (macrophage INTERGENE sub-
jects) are presented in Table 1. The atherosclerotic subjects
had higher total cholesterol levels and higher systolic
blood pressure compared to the healthy control subjects.
The different studies in the project were approved by the
ethics committees of Göteborg University and Karolinska
Institute.
Macrophage preparation and culture
Human mononuclear cells were isolated by Ficoll-Paque
(Amersham Biosciences, Uppsala, Sweden) using buffy
coats from the atherosclerotic subjects or healthy control
subjects in the macrophage INTERGENE study or healthy
volunteers. The mononuclear cell preparations were
washed five times with PBS, pH 7.2, without calcium and
magnesium, but containing 10 mM EDTA. The cell prepa-
ration was performed at room temperature. Mononuclear
cells were resuspended and seeded at a density of 107 cells
per each 100-mm plastic dish in a serum-free medium
(Macrophage-SFM, GIBCO BRL; Grand Island, NY), sup-
plemented with penicillin 100 U/ml and streptomycin
100 µg/ml. The mononuclear cells were allowed to adhere
for 1 h. Non-adhered cells were eliminated with three
washes with PBS. Adherent monocytes were cultured in
Macrophage-SFM medium with antibiotics and supple-
mented with human granulocyte macrophage colony
stimulating factor (GM-CSF), 70 U/ml (R&D Systems
Europe Ltd., Abingdon, UK). The medium was discarded
after 3d and the cells were washed once with PBS. The cells
were then allowed to grow for another 3d in the same
medium, but without GM-CSF and were then defined as
monocyte-derived macrophages, and referred to as "mac-
rophages" in the following text.
Preparation of human LDL and cell treatment
Preparation of LDL was performed as previously described
[21]. Minimally modified LDL (mmLDL) was generated
by storing sterile native LDL in the dark at 4°C for three
months (thiobarbituric acid-reactive substances (TBARS)
= 5 nmol MDA/mg protein). Macrophages from healthy
volunteers or from subjects in the macrophage INTER-
GENE study were incubated without (control) or with
mmLDL (50 µg protein/ml) in Macrophage-SFM medium
for 24 h. Macrophages from healthy volunteers were also
incubated under normoxic (21% O2) or hypoxic (0% O2)
conditions for 24 h as previously described [22]. Total
RNA was isolated from the macrophages using RNeasy kit
(Qiagen, Hilden, Germany).
Real-time PCR analysis of SR-BI gene expression
Oligonucleotide primers and probes were designed with
Primer Express 1.5 software (Applied Biosystems, Foster
City, CA). Primers (forward: 5'-CCG CAC CTT CCA GTT
CCA-3', reverse: 5'- ATG TTG GGC ATG ACG ATG TAG
TC-3') and probe (5'-TCC AAG TCC CAC GGC TCG GAG
A-3') were purchased from Applied Biosystems. These
primers detects both SR-BI and the SR-BII isoform mRNA.
The probes consisted of oligonucleotides that were
labeled at the 5' end with the reporter dye FAM and at the
3' end with the quencher TAMRA. Reagents (TaqMan®
Reverse Transcriptase reagents and TaqMan®  Universal
PCR Master mix, Applied Biosystems) and conditions
were used according to the manufacturer's protocol.
Briefly, cDNA was synthesized using reverse transcriptase
(RT) from RNA samples. Each amplification reaction
consisted of diluted cDNA (corresponding to 20 ng RNA),
300 nM of each primer, 200 nM TaqMan probe and
Table 1: Clinical and biochemical characteristics of the study groups (The macrophage INTERGENE subjects).
Characteristic Healthy control subjects (n = 15) Atherosclerotic subjects (n = 15)
Age1 (years) 57 (47–73) 58 (43–74)
Weight (Kg) 79 ± 13 80 ± 13
Systolic blood pressure (mmHg) 126 ± 14 144 ± 16*
Diastolic blood pressure (mmHg) 74 ± 8 78 ± 11
Serum Na (mmol/L) 140 ± 2 140 ± 2
Serum K (mmol/L) 4.10 ± 0.26 4.11 ± 0.27
Serum Ca (mmol/L) 2.36 ± 0.07 2.37 ± 0.07
Blood Hb (g/L) 142 ± 6 143 ± 9
Blood glucose (mmol/L) 5.1 ± 0.8 5.0 ± 0.7
Total cholesterol (mmol/L) 5.33 ± 0.64 5.99 ± 0.69*
LDL cholesterol (mmol/L) 3.23 ± 0.72 3.78 ± 0.75
HDL cholesterol (mmol/L) 1.56 ± 0.50 1.40 ± 0.49
Serum triglycerides (mmol/l) 1.37 ± 0.46 1.78 ± 1.07
Data are presented as means ± SD. 1mean and range. *P < 0.05 (Student's t-test).BMC Cardiovascular Disorders 2005, 5:25 http://www.biomedcentral.com/1471-2261/5/25
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TaqMan® Universal PCR reaction mix. Amplification and
detection of specific products were performed with the
ABI Prism 7700 sequence detection system (Applied Bio-
systems) using default cycle parameters. Pre-developed
assay reagents for human RPLP0 (large ribosomal pro-
tein) was obtained from Applied Biosystems and used as
reference to normalize the expression levels between the
samples. All standards and samples were analyzed in
triplicates.
Analysis of SR-BI isoforms by reverse transcriptase -PCR
As an isoform of SR-BI, SR-BII, is expressed in mouse tis-
sue and human cell lines, primers able to detect both iso-
forms were used (Figure 3A). Total RNA was isolated from
macrophages from healthy volunteers and from athero-
sclerotic plaque tissue using the RNeasy kit (Qiagen,
Hilden, Germany). RNA was reverse transcribed using
random hexamers and 20 units AMV-reverse transcriptase
(Promega Corp., Madison, WI). PCR was performed in
Taq buffer (Roche Diagnostics, Mannheim, Germany)
with 2 units of Taq polymerase (Roche Diagnostics), 1 µM
of primers hCLA-1 z5 (5'-GGG AAG ATC GAG CCA GTA-
3'; Genset, Paris, France) and hCLA-1 z3 Not I (5'-GCG
CGG CCG CGG GGA CAG TGT GAC ATC T-3'; Genset),
400 ng cDNA and dNTPs (0.2 mM each) using GeneAmp
PCR system 9600 (Perkin-Elmer, Foster City. CA). The
amplification is predicted to generate a 476 bp fragment
for the SR-BI transcript and a 347 bp fragment for the SR-
BII transcript. PCR products and Nco I-digested PCR prod-
ucts were separated on a 3% agarose gel containing ethid-
ium bromide. The PCR products were cloned into the
pCRII vector (Invitrogen, San Diego, CA) and verified by
DNA sequencing.
Statistical analysis
Statistical analyses were performed using Student's t-test
or by ANOVA followed by Student's t-test.
Results
Effect of hypoxia on macrophage SR-BI expression
As the thickness of the atherosclerotic plaque increases,
diffusion of oxygen is decreased and zones of low oxygen
tension can be detected within atherosclerotic plaques.
Several studies have shown that hypoxia alters a large
number of macrophage functions [2]. We therefore inves-
tigated if macrophage SR-BI expression is regulated by
hypoxia in vitro. Human macrophages from 13 healthy
volunteers were exposed to hypoxia for 24 h. The expres-
sion of macrophage SR-BI was decreased from 1.26 ± 0.17
arbitrary units to 0.73 ± 0.10 arbitrary units (mean ± SEM;
p < 0.005) after hypoxia exposure as determined by real-
time RT-PCR analysis.
Effect of mmLDL on macrophage SR-BI expression
The uptake of lipids and cholesterol by macrophages is a
key event implicated in the development of atherosclero-
sis. Therefore, scavenger receptor expression is thought to
be a critical determinant of lipid accumulation in macro-
phages. Human macrophages from 4 healthy volunteers
were treated with mmLDL (50 µg protein/ml) for 24 h.
The expression of SR-BI was significantly up regulated in
macrophages after mmLDL treatment compared to con-
Effect of mmLDL on the expression of SR-BI in macrophages Figure 1
Effect of mmLDL on the expression of SR-BI in mac-
rophages. Macrophages from 4 different healthy voluntary 
donors were exposed to mmLDL (50 µg protein/ml) for 24 h 
and SR-BI gene expression was analyzed by real-time RT-
PCR using RNA from mmLDL treated and untreated control 
macrophages. The primers for real-time RT-PCR analysis 
used in this experiment were designed to detect SR-BI and 
the SR-BI isoforms. SR-BI expression was normalized to the 
reference gene RPLP0. The results are presented as mean +/
- SEM. *, p < 0.005.
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trol macrophages (p < 0.05, Figure 1) as determined by
real-time RT-PCR analysis.
Expression of SR-BI in macrophages derived from subjects 
with atherosclerosis
As SR-BI expression in macrophages may modulate the
development of atherosclerosis we investigated if macro-
phages derived from subjects with atherosclerosis dis-
played an altered expression pattern compared to
macrophages derived from matched healthy controls. SR-
BI gene expression in macrophages and mmLDL-treated
macrophages from 15 atherosclerotic subjects and 15 con-
trols (the macrophage INTERGENE subjects) were ana-
lyzed by real-time RT-PCR (Figure 2). No difference in
gene expression was detected between the subjects with
atherosclerosis and the matched healthy controls (Figure
2). However, the analysis confirms the previous findings
that SR-BI expression is increased in response to 24 h
mmLDL treatment of macrophages from both the subjects
with atherosclerosis and the control subjects (p < 0.05 and
p < 0.05, respectively). Macrophage SR-BI expression lev-
els were not correlated to serum HDL cholesterol levels in
the macrophage INTERGENE subjects (data not shown).
Analysis of SR-BI isoforms in macrophages and 
atherosclerotic plaques
As different isoforms of SR-BI may modulate receptor
function [23], the expression of SR-BI isoforms was inves-
tigated in human macrophages by RT-PCR using primers
designed to detect both SR-BI and SR-BII transcripts. SR-BI
(476 bp) and SR-BII (347 bp) transcripts were detected in
all the samples examined (Figure 3B). The identities of the
PCR products were verified by restriction enzyme map-
SR-BI expression in macrophages from atherosclerotic  subjects Figure 2
SR-BI expression in macrophages from atheroscle-
rotic subjects. Macrophages from 15 atherosclerotic sub-
jects and 15 healthy matched control subjects were treated 
with mmLDL (50 µg protein/ml) for 24 h. SR-BI expression 
was analyzed in both groups both before and after mmLDL 
treatment by real-time RT-PCR. SR-BI expression was nor-
malized to the reference gene RPLP0. The primers for real-
time RT-PCR analysis used in this experiment detect SR-BI 
and the SR-BI isoforms. The results are presented as mean +/
- SEM. *, p < 0.05.
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Analysis of SR-BI expression in human macrophages and  human carotid atherosclerotic plaque by RT-PCR Figure 3
Analysis of SR-BI expression in human macrophages 
and human carotid atherosclerotic plaque by RT-
PCR. Schematic illustration of the human SR-BI cDNA and 
the location of the primers used for PCR (A). Analysis of 
expression of SR-BI and SR-BI isoforms in RNA extracted 
from macrophages by RT-PCR (B). PCR products from four 
donors (D1–D4) and PCR products from donor 4 digested 
with Nco I (D4+Nco I), non-template control (ntc), 1 kb 
DNA-molecular marker (m). Analysis of expression of SR-BI 
and SR-BI isoforms in RNA extracted from atherosclerotic 
plaque tissue by RT-PCR (C). PCR products from atheroscle-
rotic plaque tissue cDNA from four patients (P1–P4), PCR 
product from patient 4 digested with Nco I (P4+Nco I). PCR 
product corresponding to undigested SR-BI (476 bp), SR-BII 
(347 bp) and SR-BIII (541 bp) are indicated.BMC Cardiovascular Disorders 2005, 5:25 http://www.biomedcentral.com/1471-2261/5/25
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ping. Digestion with Nco I resulted in a 53-bp decrease in
fragment size of both SR-BI (423 bp) and SR-BII (294 bp)
as predicted from the mRNA sequence. Sequence analysis
of the 347 bp PCR product (clones from 2 subjects) con-
firmed that this isoform is the human equivalent to the
SR-BII isoform originally cloned in mouse. An additional
PCR product that decreased in size with Nco I digestion
was also detected. The PCR product (541 bp) was
sequenced (clones from 2 subjects) and identified as a
novel isoform of the SR-BI receptor and was therefore des-
ignated SR-BIII (GenBank accession number AF254409).
This novel isoform appears to be generated by the use of
an alternative splice acceptor site in intron 11, resulting in
a frame shift after aa 467, and can be predicted to generate
a unique intracellular C-terminal domain containing 53
aa (Figure 4A and 4B).
To analyze whether the SR-BI isoforms were also
expressed in human atherosclerotic plaque tissue, the
experiment was repeated using RNA samples from
plaques obtained from four patients that underwent
carotid endarterectomy. PCR products corresponding to
SR-BI (476 bp), SR-BII (347 bp) and SR-BIII (541 bp)
were detected in atherosclerotic plaques from all four
patients analyzed (Figure 3C).
Analysis of the intracellular C-terminal domain of the SR-
BI isoforms
SR-BI and SR-BI isoforms are predicted to contain two
transmembrane domains and two intracellular domains
at the amino (N)- and carboxy (C)-termini, respectively.
The N-terminal intracellular domain of SR-BI is predicted
to contain 8 amino acids (aa) and the C-terminal intracel-
lular domain of SR-BI is predicted to consist of 47 aa. A
peroxisomal targeting sequence (PTS1) is present in the C-
terminal domain of SR-BI, which is not present in the SR-
BII and SR-BIII isoforms [8,24]. The intracellular C-termi-
nal domain of human SR-BII contains 44 aa and has a
high content of proline aa (12 of 44 aa). The predicted
amino acid sequences of SR-BII from other species also
have high proline content in the intracellular C-terminal
domain (Figure 5B). The prolines in human SR-BII are in
some places interspersed with two other amino acids
generating PXXP motifs. The PXXP motif is the minimal
consensus binding-motif for src homology 3 (SH3)
domain-containing proteins [25]. One of these PXXP
motifs (aa 488–491 of SR-BII) is conserved between spe-
cies (Figure 5B). The novel SR-BIII transcript is predicted
to encode an intracellular C-terminal domain that is
longer (53 aa) than the intracellular C-terminal domains
of both SR-BI and SR-BII (Figure 5A). The C-terminal
domain of SR-BIII is less proline-rich than SR-BII and one
SH3 binding site in SR-BIII is conserved between species
(Figure 5B).
Discussion
The key role of SR-BI in the development of atherosclero-
sis has been shown in genetically modified mice models.
In particular, hepatic overexpression of SR-BI reduces
atherosclerotic lesion formation [9], which is attributed to
the role of SR-BI in the uptake of HDL-cholesterol in the
liver. This is supported by the finding that SR-BI disrup-
tion increases plaque formation [26]. Genetically modi-
fied mice models have also been used to investigate the
role of macrophage SR-BI expression in the development
of atherosclerosis. Bone marrow transplantation studies
have shown that SR-BI disruption in macrophages aug-
ment the development of advanced atherosclerotic
plaques [10,27]. This effect is attributed to SR-BI role in
cholesterol efflux. However, a recent study by Van Eck et
al  shows that the development of early atherosclerotic
plaque (fatty streaks) is reduced in macrophages lacking
SR-BI expression [28]. This effect could be related to the
scavenger receptor function of SR-BI by enhancing uptake
of oxidized LDL or VLDL [28]. This indicates that macro-
Alternative splicing generating SR-BI, SR-BII, and SR-BIII  transcripts Figure 4
Alternative splicing generating SR-BI, SR-BII, and SR-
BIII transcripts. Schematic illustration of the predicted 
alternative splicing generating the SR-BI, SR-BII, and SR-BIII 
transcripts (A). White boxes indicate exons, arrows indicate 
stop codons, black boxes indicate the part coding for the C-
terminal transmembrane domain and the gray box indicates 
the alternative reading frame used in the SR-BIII isoform. 
Nucleotide and amino acid sequence of the human SR-BI, SR-
BII, and SR-BII isoforms (B). Putative stop codons are 
underlined.BMC Cardiovascular Disorders 2005, 5:25 http://www.biomedcentral.com/1471-2261/5/25
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phage SR-BI probably plays multiple roles in the develop-
ment of atherosclerosis.
As the thickness of the atherosclerotic plaque increases,
diffusion of oxygen is decreased and zones of low oxygen
tension within atherosclerotic plaques have been detected
Intracellular domains of SR-BI isoforms Figure 5
Intracellular domains of SR-BI isoforms. Schematic illustration of the topology of the three isoforms (A). The PTS1 
domain of SR-BI, the proline-rich domain of SR-BII and the lengths of the intracellular domains are indicated. Species alignment 
of the intracellular domain of SR-BI, SR-BII and SR-BIII (B). Bovine, pig, hamster, rat and mouse SR-BIII sequences were 
deduced from SR-BI mRNAs. Sequence identities (dark gray boxes) are indicated. The isoforms differ in amino acid sequence 
downstream of Gln-467 (arrow). The PTS1 motif of SR-BI (white bold characters), and proline residues of the Src Homology 
(SH3) binding motif (black bold) are indicated. Potential sites for protein kinases A and C dependent phosphorylation, SH2 and 
SH3 binding motifs are indicated by bars.
A
BBMC Cardiovascular Disorders 2005, 5:25 http://www.biomedcentral.com/1471-2261/5/25
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[3]. In this study we show for the first time that SR-BI gene
expression is down regulated by hypoxia. Reduced macro-
phage SR-BI gene expression during hypoxic condition
may lead to reduced cholesterol efflux from macrophages
in hypoxic zones of the atherosclerotic plaque and may
increase foam cell formation in these areas.
Previous studies have shown disparate effect of highly oxi-
dized LDL (oxLDL) on SR-BI expression in human mono-
cyte-derived macrophages. Hirano et al reported an
increased expression of SR-BI during macrophage differ-
entiation and that oxLDL induced SR-BI mRNA and pro-
tein expression after 24 h of treatment [29]. In contrast,
Han  et al reported that 10 days differentiated macro-
phages displayed a decreased SR-BI expression in response
to 16 h oxLDL treatment [30]. However, less differentiated
macrophages (3 days differentiation) responded to 16 h
of oxLDL treatment with increased SR-BI expression [30].
This indicates that the differentiation status of the macro-
phages and the time of oxLDL treatment influences SR-BI
expression. In this study we show that SR-BI expression in
macrophages is increased in response to 24 h of mmLDL
treatment. Differences in chemical properties of mmLDL
compared to oxLDL can affect macrophage SR-BI expres-
sion. It is unclear which of these in vitro foam cell forma-
tion models that best resembles foam cell formation in
vivo.
It has been suggested that genetic variants involved in the
development of complex disorders such as atherosclero-
sis, are often located in regulatory regions of the genome
and affect the transcription of the susceptibility gene. As
SR-BI gene expression in macrophages may modulate the
development of atherosclerosis we investigated if
macrophages derived from subjects with atherosclerosis
displayed an altered expression pattern compared to mac-
rophages derived from matched healthy controls. The
results of this experiment indicate that altered expression
of SR-BI in macrophages is not a common component in
the development on atherosclerosis in the Swedish
population. Recently, a variant of the human SR-BI pro-
moter has been identified in a Taiwanese Chinese popula-
tion. This promoter variant displays decreased gene
expression and has been associated to increased plasma
HDL cholesterol levels [16]. However, the allele frequency
of this functional variant is rather low. SR-BI and mem-
bers of the ATP-binding cassette transporters have been
shown to facilitate cellular cholesterol efflux. SR-BI
mainly binds phospholipid-rich HDL particles, whereas
ABCA1 preferably uses lipid-poor HDL particles as choles-
terol acceptors [31]. However, the precise role and interac-
tions between these proteins is not completely
understood.
The presence of multiple SR-BI isoforms in macrophages
and atherosclerotic plaques makes the interpretation of
the role of SR-BI in human atherosclerosis complex. We
have previously identified a PTS1 motif in the C-terminus
of SR-BI [8,24], which is not present in SR-BII and SR-BIII.
The PTS1 motif is recognized by the peroxisomal targeting
import receptor Pex5p [32], which mediates uptake of
proteins in the peroxisome and may therefore be of
importance for SR-BI action as the peroxisome is an
important subcellular site for cholesterol and bile acid
metabolism. A protein from rat liver membrane extracts
named CLAMP has been shown to interact with the C-ter-
minal end of SR-BI [33]. The human SR-BII isoform was
also detected in macrophages and atherosclerotic plaques.
The mouse SR-BII isoform binds HDL and mediates both
cholesterol uptake and efflux but seems to be less efficient
than SR-BI [23]. Lower surface expression or reduced sta-
bility of SR-BII compared to SR-BI may contribute to the
differences between the two molecules [24]. It has
recently been shown that SH3 domain containing pro-
teins may interact with the SR-BII C-terminal domain
[34]. This indicates that the different SR-BI isoforms may
have distinct functional and signaling properties.
We have identified a novel isoform of SR-BI, SR-BIII,
which is expressed in macrophages and atherosclerotic
plaques. The SR-BIII isoform is probably generated by the
use of an alternative splice acceptor site in intron 11 and
encodes a unique intracellular C-terminal of the receptor.
Further studies are needed to determine if SR-BIII also
functions as a HDL receptor and what physiological func-
tion it may have.
Conclusion
We conclude that SR-BI is regulated by proatherogenic
stimuli such as hypoxia and mmLDL in human macro-
phages. However, no differences in SR-BI expression were
detected between macrophages from subjects with athero-
sclerosis and healthy controls. This indicates that altered
SR-BI expression is not a common feature of atherosclero-
sis. In addition, we identified SR-BIII as a novel SR-BI iso-
form expressed in human macrophages and in human
atherosclerotic plaques.
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